Pharmaceutical Giant Beats Wall Street Expectations While Hiking Prices on
Brand Name Drugs





 



BIG PHARMA EARNINGS WATCH: JOHNSON & JOHNSON

Pharmaceutical Giant Beats Wall Street Expectations While Hiking Prices on
Brand Name Drugs



Last week, Johnson & Johnson reported earnings for the second quarter of the
year that beat Wall Street analysts’ expectations after already hiking
prescription drug prices 30 times just so far this year. Johnson & Johnson has
consistently beat Wall Street analysts’ revenue expectations for years,
including in2019
<[link removed]>, 2020
<[link removed]>,
2021 <[link removed]>, 2022
<[link removed]>
,2023 <[link removed]>and
2024 <[link removed]> —
while repeatedly hiking prices on brand name products and deploying
anti-competitive tactics to undermine competition from more affordable
alternatives.



Get the full recap of Johnson & Johnson’s Q2 earnings here:



Johnson & Johnson

* Johnson & Johnson reported strong earnings
<[link removed]>
that beat Wall Street analysts’ expectations for the second quarter in a row.
* The company raised its sales outlook for 2025 to the range of $93.2 billion
to $93.6 billion
<[link removed]>
, up from $91 billion to $91.42 billion.
* The Big Pharma giant saw sales of $23.74 billion
<[link removed]>
, beating expectations of $22.84 billion.
* Johnson & Johnson’s medical device division saw $8.5 billion
<[link removed]> in
sales, beating the consensus estimate.
* Darzalex, a multiple myeloma drug, brought in Q2 quarter sales of $3.38
billion
<[link removed]>
.
Johnson & Johnson’s strong earnings follow a consistent record of hiking
prices on brand name drugs and undermining competition in the market:


Johnson & Johnson

* Johnson & Johnson has hiked prices on 30 prescription drugs
<[link removed]> in 2025, including a 5.5
percent increase on multiple myeloma drug Darzalex and a 4.7 percent increase
on psoriasis drug Stelara.
* Johnson & Johnson engaged in 35 price hikes
<[link removed]> in 2024, including a 6.3
percent increase on Darzalex, and five percent increases on Erleada and Stelara.
* According to a December 2024 ICER report
<[link removed]>, price
hikes that were unsupported by new clinical evidence on multiple myeloma drug
Darzalex led to additional consumer spending of$190 million
<[link removed]>.
* Johnson & Johnson also engaged in 36 price hikes
<[link removed]>in 2023, including a 4.5 percent
increase on Darzalex, a five percent increases on Erleada and a four percent
increase on Stelara.
* Spending on the company’s blockbuster cancer drug Imbruvica is expected to
exceed $41 billion <[link removed]>between 2027-2036 thanks
to an anti-competitive patent scheme that extended a monopoly on the
high-priced cancer drug by more than nine years. Imbruvica costs an eye-popping
$180,000 per year
<[link removed]>
.
Stay tuned as we continue to monitor second quarter earnings calls from brand
name drug companies in the coming weeks.



Learn more about solutions to lower prescription drug prices and hold Big
Pharma accountableHERE <[link removed]>.



###

































Copyright © 2019 Campaign for Sustainable Rx Pricing
Our address is 1341 G St NW, #1100, Washington, DC xxxxxx


This email was sent to [email protected]. To unsubscribe please click
here.
<[link removed]>